PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients

Journal of Hepatology

Volumn 63, Issue 3, 2015, Pages 651-660

  Han, Tao ^a   Xiang, Dai Min ^a   Sun, Wen ^a   Liu, Na ^a   Sun, Huan Lin ^a   Wen, Wen ^a   Shen, Wei Feng ^b   Wang, Ruo Yu ^b   Chen, Cheng ^a   Wang, Xue ^a   Cheng, Zhuo ^a   Li, Heng Yu ^a   Wu, Meng Chao ^b   Cong, Wen Ming ^b   Feng, Gen Sheng ^c   Ding, Jin ^a,d   Wang, Hong Yang ^a,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d National Scientific Centre for Liver Cancer   (China)

Author keywords

Hepatocellular carcinoma; Metastasis; Prognosis; Shp2

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAS PROTEIN; SHORT HAIRPIN RNA; SORAFENIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PTPN11 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEPATOMA CELL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; LIVER NEOPLASMS; MORTALITY; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RAF KINASES;

EID: 84939170655     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.036     Document Type: Article

References (50)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J Clin 62 2012 10 29
3. H.B. El-Serag Hepatocellular carcinoma: an epidemiologic view J Clin Gastroenterol 35 2002 S72 S78
4. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
5. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
6. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 2003 915 925
7. A. de La Coste, B. Romagnolo, P. Billuart, C.A. Renard, M.A. Buendia, O. Soubrane, and et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc Natl Acad Sci U S A 95 1998 8847 8851
8. T. Takami, P. Kaposi-Novak, K. Uchida, L.E. Gomez-Quiroz, E.A. Conner, V.M. Factor, and et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis Cancer Res 67 2007 9844 9851
9. S. Maeda, H. Kamata, J.L. Luo, H. Leffert, and M. Karin IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis Cell 121 2005 977 990
10. M. Das, D.S. Garlick, D.L. Greiner, and R.J. Davis The role of JNK in the development of hepatocellular carcinoma Genes Dev 25 2011 634 645
11. X.F. Zhang, X. Tan, G. Zeng, A. Misse, S. Singh, Y. Kim, and et al. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling Hepatology 52 2010 954 965
12. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, and et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
13. R.M. Freeman Jr., J. Plutzky, and B.G. Neel Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew Proc Natl Acad Sci U S A 89 1992 11239 11243
14. M. Adachi, M. Sekiya, T. Miyachi, K. Matsuno, Y. Hinoda, K. Imai, and et al. Molecular cloning of a novel protein-tyrosine phosphatase SH-PTP3 with sequence similarity to the src-homology region 2 FEBS Lett 314 1992 335 339
15. G.S. Feng, C.C. Hui, and T. Pawson SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases Science 259 1993 1607 1611
16. A. Lisa, C.Z. Lai, E. Eric, Zhang, and G.-S. Feng The Shp-2 tyrosine phosphatase Top Curr Genet 5 2004 275 299
17. B.G. Neel, H. Gu, and L. Pao The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem Sci 28 2003 284 293
18. M. Tartaglia, E.L. Mehler, R. Goldberg, G. Zampino, H.G. Brunner, H. Kremer, and et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nat Genet 29 2001 465 468
19. M. Tartaglia, and B.D. Gelb Germ-line and somatic PTPN11 mutations in human disease Eur J Med Genet 48 2005 81 96
20. R.J. Chan, and G.S. Feng PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase Blood 109 2007 862 867
21. N. Aceto, N. Sausgruber, H. Brinkhaus, D. Gaidatzis, G. Martiny-Baron, G. Mazzarol, and et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop Nat Med 18 2012 529 537
22. C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, and et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration Cancer Res 67 2007 4278 4286
23. Y. Zhan, G.J. Counelis, and D.M. O'Rourke The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells Exp Cell Res 315 2009 2343 2357
24. E.A. Bard-Chapeau, J. Yuan, N. Droin, S. Long, E.E. Zhang, T.V. Nguyen, and et al. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection Mol Cell Biol 26 2006 4664 4674
25. E.A. Bard-Chapeau, S. Li, J. Ding, S.S. Zhang, H.H. Zhu, F. Princen, and et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis Cancer Cell 19 2011 629 639
26. W. Sun, J. Ding, K. Wu, B.F. Ning, W. Wen, H.Y. Sun, and et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells Hepatology 54 2011 1259 1272
27. J. Fu, Y. Chen, J. Cao, T. Luo, Y.W. Qian, W. Yang, and et al. P28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways Hepatology 53 2011 181 192
28. W. Wen, J. Ding, W. Sun, J. Fu, Y. Chen, K. Wu, and et al. Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression Hepatology 55 2012 1787 1798
29. K. Wu, J. Ding, C. Chen, W. Sun, B.F. Ning, W. Wen, and et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development Hepatology 56 2012 2255 2267
30. T.A. Yap, M.D. Garrett, M.I. Walton, F. Raynaud, J.S. de Bono, and P. Workman Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises Curr Opin Pharmacol 8 2008 393 412
31. A. Forner, J.M. Llovet, and J. Bruix Hepatocellular carcinoma Lancet 379 2012 1245 1255
32. M. Maluccio, and A. Covey Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma CA Cancer J Clin 62 2012 394 399
33. S. Li, D.D. Hsu, H. Wang, and G.S. Feng Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis Front Med 6 2012 275 279
34. M.L. Loh, S. Vattikuti, S. Schubbert, M.G. Reynolds, E. Carlson, K.H. Lieuw, and et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis Blood 103 2004 2325 2331
35. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
36. R. Xu, Y. Yu, S. Zheng, X. Zhao, Q. Dong, Z. He, and et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia Blood 106 2005 3142 3149
37. Q.H. Ye, L.X. Qin, M. Forgues, P. He, J.W. Kim, A.C. Peng, and et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning Nat Med 9 2003 416 423
38. G.S. Feng Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox Cancer Cell 21 2012 150 154
39. C. Jiang, F. Hu, Y. Tai, J. Du, B. Mao, Z. Yuan, and et al. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma J Cancer Res Clin Oncol 138 2012 637 646
40. X. Zhao, S. Hu, L. Wang, Q. Zhang, X. Zhu, H. Zhao, and et al. Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations PLoS One 9 2014 e106841
41. M. Bentires-Alj, J.G. Paez, F.S. David, H. Keilhack, B. Halmos, K. Naoki, and et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia Cancer Res 64 2004 8816 8820
42. S.M. Ahn, S.J. Jang, J.H. Shim, D. Kim, S.M. Hong, C.O. Sung, and et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification Hepatology 60 2014 1972 1982
43. A. Fujimoto, Y. Totoki, T. Abe, K.A. Boroevich, F. Hosoda, H.H. Nguyen, and et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators Nat Genet 44 2012 760 764
44. J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, and et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 6 2013 pl1
45. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, and et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2 2012 401 404
46. Y. Ke, E.E. Zhang, K. Hagihara, D. Wu, Y. Pang, R. Klein, and et al. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality Mol Cell Biol 27 2007 6706 6717
47. T. Burdon, C. Stracey, I. Chambers, J. Nichols, and A. Smith Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells Dev Biol 210 1999 30 43
48. G.S. Feng Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation Cell Res 17 2007 37 41
49. J. Ding, and H. Wang Multiple interactive factors in hepatocarcinogenesis Cancer Lett 346 2014 17 23
50. P. Yue, and J. Turkson Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18 2009 45 56